Targeting the Apelinergic signaling pathway to drive improved health outcomes
Therapeutic Drug Development Pipeline
Systemic sclerosis (SSc) / Systemic sclerosis interstitial lung disease (SSc-ILD)
Idiopathic Pulmonary Fibrosis (IPF)
Kidney Nephrotic Syndrome
APIE Therapeutics is the leader in harnessing the Apelin-APJ signaling pathway to develop successful therapeutic drugs for chronic and fibrotic diseases. A strong global intellectual property portfolio supports our unique approach to targeting the apelinergic system.
The Initial Challenge
Discovering active, potent, and highly selective agonists to the Apelin Receptor (APJ) is challenging because endogenous apelin peptides are non-selective with a short half-life that limits their utility.
APIE Therapeutics Apelin Receptor (APJ) Agonists Discovery Platform
RTI International (RTI), a well-known research organization and investors of commercial drugs such as Taxol®, Camptothecin®, EllaOne®, and Esmya®, with NIH funding support, pioneered the design and discovery of a novel Apelin drug-like agonist scaffold that selectively binds to the Apelin receptor. Modifications were then made to the core scaffold to generate over 800 synthetic analogs spanning several chemotypes with varying potency and selectivity for the Apelin-APJ receptor. Challenge conquered!
We are continually evaluating the therapeutic effects of our lead compounds to create a portfolio of drug development programs that can be moved into clinical trials via investments and/or partnerships.
APIE Therapeutics has a strong IP portfolio of several issued patents with broad supported claims covering many variations on the base scaffold including the lead compound of interest. These patents have long patent life remaining (2037 and beyond) and have been filed extensively internationally. The patent portfolio contains several family members with different structural classes and methods of use filed later to provide additional patent protection and term.